AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01039792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04160117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
Study NCT04160117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
Study NCT04603846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-L1 antibody
Description: Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
Study NCT04603846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin bound paclitaxel
Description: Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .
Study NCT02439723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study NCT03131154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Solution (0.5%)
Description: ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
Study NCT03131154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of ADX-102 Ophthalmic Solution
Description: Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
Study NCT03394729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis tablet to limit dental biofilm
Description: The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days
Study NCT03394729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xilytol tablet to limit dental biofilm
Description: The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days.
Study NCT04298697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Description: TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
Study NCT03594513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCAF
Description: Periodontal surgical technique to treat gingival recessions.
Study NCT03594513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCAF
Description: Periodontal surgical technique to treat gingival recessions.
Study NCT03594513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PR
Description: Restorative procedure to treat tooth structure loss.
Study NCT03594513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PR
Description: Restorative procedure to treat tooth structure loss.
Study NCT03594513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG
Description: Autogenous graft harvested from palate placed in the surgical site.
Study NCT03594513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XMD(Mucoderm®)
Description: Xenogenous graft placed in the surgical site.
Study NCT03594513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium dipyrone
Description: All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
Study NCT03594513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium dipyrone
Description: All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
Study NCT03594513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine rinse
Description: All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
Study NCT03594513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine rinse
Description: All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
Study NCT01808755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D Mannose
Description: 1 gr. every 8 hours
Study NCT01808755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D Mannose
Description: 1 gr. every 8 hours
Study NCT01808755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim/sulfamethoxazole
Description: one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
Study NCT01808755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim/sulfamethoxazole
Description: one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
Study NCT04242953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCO-120
Description: Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)
Study NCT04242953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: Part A: single oral administration~Part C: multiple oral administration (14 day dosing)
Study NCT03167749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory test
Description: Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
Study NCT03735303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3 group
Description: VD3 50000 IU/ week for 8 weeks
Study NCT03735303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 3 FA group
Description: omega 3 FA group 300 mg once daily for 8 weeks
Study NCT03735303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3 and omega- 3FA group
Description: 50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
Study NCT03735303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: no intervention was given
Study NCT00352768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate
Description: Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
Study NCT00352768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02135250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xinkeshu tablets
Description: 4 Xinkeshu tablets are given three times per day
Study NCT02135250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: the placebo is not drug.
Study NCT01054014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40346527/Placebo
Description: Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
Study NCT01054014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40346527/Placebo
Description: JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
Study NCT01054014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40346527
Description: JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
Study NCT02474316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
Study NCT02474316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nucleos(t)ide analgoue
Description: nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
Study NCT02474316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nucleos(t)ide analgoue
Description: nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
Study NCT01874002 — intervention group
Intervention type: DEVICE
Intervention: Combo stent
Description: Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
Study NCT01521117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
Study NCT01521117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
Study NCT03773640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio frequency currents
Description: Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
Study NCT03773640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sonophoresis
Description: The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
Study NCT00437112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 24 weeks
Study NCT00437112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: patient specific dose, injectable, before meals, 24 weeks
Study NCT01394237 — intervention group
Intervention type: OTHER
Intervention: Examination
Description: Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
Study NCT01269203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 1000 mg per day
Study NCT01269203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered daily same as Curcumin.
Study NCT02575963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Phase 1 only)
Description: Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
Study NCT02575963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lintuzumab-Ac225
Description: In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
Study NCT02575963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide (Phase 1 only)
Description: 40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
Study NCT02575963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
Study NCT02743208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short stem hip arthroplasty (SHA)
Description: Furlong Evolution femoral stem
Study NCT02743208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty (THA)
Description: Furlong H-A.C. femoral stem
Study NCT03690193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: All participants will be assigned to the 3-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
Study NCT01065844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: 1250 mg Nelfinavir twice daily Monday - Sunday
Study NCT02046967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation with 940 nm bare fiber
Description: Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.
Study NCT02046967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous steam ablation with steam vein sclerosis system.
Description: Endovenous steam ablation with steam vein sclerosis.
Study NCT03558737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high-frequency jet ventilation (nHFJV)
Description: Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway
Study NCT03558737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Description: Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
Study NCT03025282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD10367 3% Solution - Non-desquamated zone
Description: Once daily application for 3 weeks
Study NCT03025282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD10367 1% Solution - Non-desquamated zone
Description: Once daily application for 3 weeks
Study NCT03025282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD10367 solution placebo - Non-desquamated zone
Description: Once daily application for 3 weeks
Study NCT03025282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betneval ointment - Non-desquamated zone
Description: Once daily application for 3 weeks
Study NCT03025282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD10367 3% Solution - Desquamated zone
Description: Once daily application for 3 weeks
Study NCT03025282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD10367 solution placebo - Desquamated zone
Description: Once daily application for 3 weeks
Study NCT00392327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT00392327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT00392327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00392327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT00392327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00392327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00392327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00392327 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given IV or SC
Study NCT00392327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC
Study NCT00392327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO
Study NCT02197559 — intervention group
Intervention type: PROCEDURE
Intervention: DES group
Description: all the participants in this group will be performed with drug -eluting stents
Study NCT02197559 — intervention group
Intervention type: PROCEDURE
Intervention: BMS group
Description: all the participants in this group will be performed with bare-metal stents
Study NCT03768583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group TSM ICT sneakers
Description: Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
Study NCT03768583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group TSM ICT barefoot
Description: Sensory motor training without sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
Study NCT03768583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group TSM health sneaker
Description: Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
Study NCT00392327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT00392327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT00392327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT00392327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT00392327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00392327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03768583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group TSM health barefoot
Description: Sensory motor training without sneaker for volunteers with Chronic ankle instability, for five weeks, twice a week.
Study NCT04201964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of tenecteplase
Description: Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
Study NCT00392327 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT00392327 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT00392327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00392327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03469947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 gram of prehospital Tranexamic Acid
Study NCT00534612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aspiration biopsy
Description: fine needle aspiration biopsy of the parotid gland masses
Study NCT02205736 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breast Health Education
Description: Small group breast health educational sessions for Latino women in home setting.
Study NCT00896402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin antisepsis with chlorhexidine
Description: Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
Study NCT00896402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: povidone-iodine
Description: Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
Study NCT01066013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial de-escalation strategy
Description: The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
Study NCT05056935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1148
Description: A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.
Study NCT05056935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.